A gene expression signature predicts survival of patients with stage I non-small cell lung cancer
2006

Gene Expression Signature Predicts Survival in Stage I Lung Cancer

Sample size: 197 publication Evidence: high

Author Information

Author(s): Lu Yan, Lemon William, Liu Peng-Yuan, Yi Yijun, Morrison Carl, Yang Ping, Sun Zhifu, Szoke Janos, Gerald William L, Watson Mark, Govindan Ramaswamy, You Ming

Primary Institution: Washington University School of Medicine

Hypothesis

Can a gene expression signature predict survival outcomes for patients with stage I non-small cell lung cancer?

Conclusion

The study identifies a 64-gene expression signature that can accurately predict survival in patients with stage I non-small cell lung cancer.

Supporting Evidence

  • The gene expression signature was validated with over 85% accuracy in independent datasets.
  • Kaplan-Meier analysis showed significant differences in survival between high-risk and low-risk groups.
  • The study combined data from multiple sources to increase sample size and statistical power.
  • Distance-weighted discrimination was used to adjust for systematic biases in the datasets.
  • 64 genes were identified as being predictive of survival outcomes.
  • Patients with high-risk signatures were more likely to have poorer survival outcomes.
  • Previous attempts to establish gene signatures lacked consistency due to small sample sizes.
  • The findings suggest potential for personalized treatment strategies based on gene expression profiles.

Takeaway

Scientists found a special set of 64 genes that can help doctors know which lung cancer patients might live longer after treatment.

Methodology

The study used a meta-analysis of seven datasets to identify differentially expressed genes related to survival in stage I lung cancer patients.

Potential Biases

Systematic biases from different microarray platforms were addressed using distance-weighted discrimination.

Limitations

The ability to predict outcomes must be confirmed in further studies before routine clinical use.

Participant Demographics

Patients included those with stage I non-small cell lung cancer, specifically adenocarcinoma and squamous cell carcinoma.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pmed.0030467

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication